NCT00722488View on ClinicalTrials.gov

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2013

Conditions
Hematologic MalignanciesMultiple MyelomaLymphomaHodgkin Lymphoma
Interventions
DRUG

MLN4924

Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

30322

Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY